Merck & Co., Inc.

MRK Healthcare & Pharma 3/10 Low Risk
3/10

Merck & Co., Inc. did not report standard long-term debt figures in its most recent 10-K. Approximately $2.6B (20% of maturities) is due within the next twelve months. Overall, MRK carries low refinancing risk (score 3/10).

Maturity Schedule

Year 1 $2.6B Year 2 $2.7B Year 3 $2.1B Year 4 $3.0B Year 5 $2.7B Beyond 5 $0
Period Amount Due % of Total
Year 1 (0-12 months) $2.6B 19.8%
Year 2 (12-24 months) $2.7B 20.6%
Year 3 (24-36 months) $2.1B 16.0%
Year 4 (36-48 months) $3.0B 22.9%
Year 5 (48-60 months) $2.7B 20.6%
Beyond 5 Years N/A N/A
Total Scheduled Maturities $13.1B 100.0%

Key Metrics

Total Long-Term Debt
N/A
Near-Term (12mo)
$2.6B
Interest Coverage
N/A
Debt/Equity
0.28
Cash Coverage
5.09x
Operating Income
N/A

Score Components

Component Value Weight
Near-Term Maturity Concentration 19.8% 30%
Interest Coverage Ratio N/A 25%
Debt-to-Equity Ratio 0.28 25%
Cash Coverage of Near-Term Debt 5.09x 20%

Related Companies

JOHNSON & JOHNSON
JNJ
1/10
Debt: $32.4B 12mo: $2.0B
PFIZER INC
PFE
5/10
Debt: $4.0B 12mo: N/A
AbbVie Inc.
ABBV
5/10
Debt: $64.5B 12mo: $6.0B
ELI LILLY & Co
LLY
3/10
Debt: $19.1B 12mo: $781M
BRISTOL MYERS SQUIBB CO
BMY
4/10
Debt: $49.4B 12mo: $2.0B
AMGEN INC
AMGN
5/10
Debt: $60.1B 12mo: $4.6B
GILEAD SCIENCES, INC.
GILD
4/10
Debt: $26.7B 12mo: $2.8B
REGENERON PHARMACEUTICALS, INC.
REGN
1/10
Debt: N/A 12mo: N/A

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Most recent filing date: 2026-02-24. Data last fetched: 2026-03-15. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Partial.